Amarin Revenue and Competitors
Estimated Revenue & Valuation
- Amarin's estimated annual revenue is currently $145.7M per year.
- Amarin's estimated revenue per employee is $288,564
- Amarin's total funding is $122.8M.
Employee Data
- Amarin has 505 Employees.
- Amarin grew their employee count by 0% last year.
Amarin's People
| Name | Title | Email/Phone |
|---|---|---|
1 | EVP, Chief Legal & Compliance Officer, and Corporate Secretary | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | Head Global Supply Chain & External Manufacturing | Reveal Email/Phone |
4 | SVP, Corporate Business Development | Reveal Email/Phone |
5 | SVP, Investor Relations & Corporate Affairs | Reveal Email/Phone |
6 | VP, Finance & System Integration | Reveal Email/Phone |
7 | VP, U.S. Sales, Marketing & Operations | Reveal Email/Phone |
8 | VP, Intellectual Property Management | Reveal Email/Phone |
9 | VP, Chemistry, Manufacturing and Controls (CMC) | Reveal Email/Phone |
10 | SVP, National Sales | Reveal Email/Phone |
Amarin Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 25 | -11% | N/A | N/A |
#2 | $35.8M | 178 | 8% | N/A | N/A |
#3 | $5.4M | 27 | -25% | N/A | N/A |
#4 | $4180M | 14516 | 1% | $550M | N/A |
#5 | $12.5M | 62 | 15% | N/A | N/A |
#6 | $6.7M | 119 | -37% | $199.6M | N/A |
#7 | $9.4M | 47 | 7% | N/A | N/A |
#8 | $10.3M | 51 | 6% | N/A | N/A |
#9 | $106.3M | 529 | 16% | N/A | N/A |
#10 | $15.5M | 77 | 20% | N/A | N/A |
What Is Amarin?
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids.
keywords:N/A
$122.8M
Total Funding
505
Number of Employees
$145.7M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Amarin News
Amarin has had a rough go of it since the patent ruling in the United States for their flagship product, Vascepa. The company is struggling...
I had given up on Amarin Corporation plc (NASDAQ:AMRN) after its plunge from the high-20s to below $10. However, a number of recent...
After Amarin lost a U.S. patent defense against generics to its sole product Vascepa, a lot of the heart drug's future hangs on its ability...
Amarin Reports Second Quarter 2014 Financial Results and Provides Update on Operations August 7, 2014 at 4:01 PM EDT Amarin Reports Second Quarter 2014 Financial Results and Provides Update on Operations126.4 KB BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 08/07/14 -- Amarin Corpor ...
Shares of Amarin fell 67% following the ruling on the Nasdaq and were down more than 68% when markets opened Tuesday. Shares of Dr. Reddy’s and Hikma were up more than 4% on the National Stock Exchange of India and 2.7% on the London Stock Exchange, respectively. Amarin has said it will appeal ...
Other Companies in Bedminster
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $194.7M | 550 | -3% | N/A |
#2 | $175.4M | 668 | 42% | N/A |
#3 | $145.5M | 724 | 30% | N/A |
#4 | $145.5M | 724 | 30% | N/A |
#5 | $429.5M | 2360 | 58% | N/A |